High prevalence of relapse in children with Philadelphia-like acute lymphoblastic leukemia despite risk-adapted treatment

Susan L Heatley, Teresa Sadras, Chung H Kok, Eva Nievergall, Kelly Quek, Phuong Dang, Barbara McClure, Nicola Venn, Sarah Moore, Jeffrey Suttle, Tamara Law, Anthea Ng, Walter Muskovic, Murray D Norris, Tamas Revesz, Michael Osborn, Andrew S Moore, Ram Suppiah, Chris Fraser, Frank Alvaro, Timothy P Hughes, Charles G Mullighan, Glenn M Marshall, Luciano Dalla Pozza, David T Yeung, Rosemary Sutton, and Deborah L White

Disclosures: Conflict of interest disclosures: TPH and DTY - Research support from Novartis, Ariad and BMS, Honoraria and Advisory role Novartis. CGM - Research support from Loxo Oncology. Scientific Advisory Board for Incyte. Speakers bureau for Amgen. DLW - Research support from Novartis and BMS, Honoraria from BMS. All other authors - no competing financial interests.

Contributions: Authorship Contributions: SLH, RS & DLW designed the research; SLH, TS, EN, PD, BMc, NV, SM, JS, TL and WM performed experiments; AN, MDN, TR, MO, ASM, RaS, CF, FA, GMM, LDP and RS provided samples and/or acquisition of clinical data; SLH, TS, CGM, DY, RoS and DLW analysed and interpreted data; CHK and KQ performed biostatistical analysis; SLH, RoS and DLW wrote the manuscript; TPH, CGM and DY contributed to writing and provided critical review of the manuscript; all other authors reviewed the manuscript.